ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO993

Soluble Form of VCAM-1 Ameliorates Podocyte Injury by Plasma Membrane PTEN Recruitment

Session Information

Category: Pathology and Lab Medicine

  • 1501 Pathology and Lab Medicine: Basic


  • Manabe, Shun, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Sakamoto, Kazuo, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Ito, Naoko, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Saga, Nobuyuki, University of Tsukuba, Tsukuba, Ibaraki, Japan
  • Nitta, Kosaku, Tokyo Women’s Medical University, Shinjuku, Tokyo, Japan
  • Nagata, Michio, University of Tsukuba, Tsukuba, Ibaraki, Japan

Various types of stresses cause epithelial-mesenchymal transitions (EMTs) and detachments of podocyte that result in glomerular sclerosis. Podocyte has self-defense mechanisms to resist against the stresses by expressing aberrant proteins. Vascular cell adhesion molecule-1 (VCAM-1) is a well-known protein induced by stresses that serve functions in membrane-bound and soluble form (sVCAM-1). However, in podocyte, the link between VCAM-1 and stress resistance remains unknown.


NEP25 transgenic mouse that develop podocyte-specific injury by immunotoxin injection were used. We assessed podocyte VCAM-1 and its ligand expressions by immunostaining, PCR, and western blot (WB). In vivo functions of sVCAM-1 were assessed by inhibiting ADAM17, the shedding enzyme of VCAM-1, by BB94. Immortalized podocyte were used for in vitro studies. The podocyte treated with H2O2, TGF-β1, sVCAM-1, and bpV were analyzed by immunostaining, real-time PCR, WB, and migration assay.


Podocyte-specific injury of NEP25 mouse induced aberrant podocyte VCAM-1 and ADAM17 expression, which suggests the generation of sVCAM-1. Human focal segmental glomerular sclerosis also expressed podocyte VCAM-1. In vivoand in vitropodocyte expressed α9β1 integrin, which is the ligand of sVCAM-1.In vitro, sVCAM-1 ameliorated TGF-β1 induced podocyte EMT; amelioration of enhanced motility, maintenance of podocyte specific proteins, and inhibition of Akt phosphorylation. Mechanistically, sVCAM-1 recruited PTEN against plasma membrane, which was shown by immunostaining and WB analysis of plasma membrane fraction protein. Blockage of PTEN by bpV diminished the efficacy of sVCAM-1 to ameliorate podocyte EMT. Finally, we treated immunotoxin-injected NEP25 mouse by BB94 to inhibit sVCAM-1 generation that resulted in exacerbation of renal disfunction, urinary protein and glomerular sclerosis.


Aberrant sVCAM-1 generation recruited PTEN against plasma membrane to ameliorate podocyte injury by inhibiting Akt phosphorylation. VCAM-1 expression might be one of the intrinsic self-defense mechanisms to resist against stresses in podocyte.